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S. Sarfaraz, N.A. Jarad 
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Aims: Determination of factors inf luencing the persistence of Pseudomonas 
aeruginosa ha sputum or oropharyngeal cultures in CF patients who are not 
chronically infected. 
Methods: 187 CF patients, mean age 16.7, were classified with regard to their status 
of Pseudomonas infection (chronic, intermittent, not infected). 24 patients with 1"7 
positive cultures during a 2 year period were identified with inter miltent infection. 
Appropriate anti Pseudomonas therapy was administered asclinically required. 
Duration of intermittent infection, frequency of Pseudomonas detection, and 
number of different pyocin typed strains were analysed relr ospectively. The cohort 
was prospectively observed with three monthly cultures over the next two years. 
Results: In 9 patients Pseudomonas was not detected within the next two years, 15 
patients showed unchanged intermittent infection. The disappearance of 
Pseudomonas depended on the total duration of intermittent Pseudomonas infection 
(3.6 vs 6.6 years, p 0.06), the frequency of positive Pseudomonas cultures (3.8 vs 
11.9, p~).002), the number of different strains (2.0 vs 4.4, p~).03), and the absence 
of antibodies against Pseudomonas (7/9 vs 5/15, p~).036). I f  Pseudomonas 
disappeared, FEV 1 was stable in the fol lowing two years, i f  not, FEGI  dropped 
(98 to 88.5 predicted, p 0.028). Anti  Pseudomonas therapy was less intense during 
the two prospective years ha patients where Pseudomonas disappeared (2/9 vs 9/15 
cycles of iv therapy, p 0.021). 
Conclusions: Disappearance of Pseudomonas aeruginosa from intermittently 
infected CF patients is more l ikely with shorter duration of infection, less positive 
cultures, less different Pseudomonas strains and the absence of antibodies against 
Pseudomonas. Patients with ongoing intermittent infection required more intense 
anti Pseudomonas therapy and nevertheless had deteriorating lung function. 
Aims: Pulmonary exacerbation is an important outcome in CF. Def in ing  
exacerbations differ between physicians. The aim of this study is to investigate 
change in symptoms and FEV1 in patients ha the period around CF pulmonary 
exacerbation. 
Methods: We use device consisting of a portable computer/mobile phone attached 
to a spit omelry. Patients are asked to complete once daily a symptom questionnaire 
scoring their symptoms of cough, sputum, breathlessness and fatigue and to perform 
spirometry on 3 occasions. Data is sent on a daily basis and sought by a group of 
researchers. Data produced on the first exacerbation free 20 days are regarded as 
baseline data. Exacerbations were regarded to have occurred it" patient sought help 
from the CF team, or i f  they have 3 days increase ha three respiratory symptoms, or 
two respiratory symptoms and 10% decline in FEV1 or three days of decline in 
FEV1 alone. 
Results: So far, 19 patients were enrolled in the study. Their mean age 24.2 years, 
range 19 34 years. Mean days recorded 67.68 % of total. From a total of 22 
exacerbations that were recorded, 14 patients registered an increase in one symptom 
and for 13 patients there was an i crease of 2 symptoms. A decl ine in FEV1 
occurred in 4 patients. The prodromal phase varied between patients. In 22 
exacerbations recorded by the e san system, a course of antibiotics was required. 
Conclusions: Our c iteria for exacerbation i this cohort of adult CF patient may 
have been too stringent. The need for treatment as felt by patient can occur by 
increase ha one or two symptoms. Precise definit ion of CF pulmonary exacerbation 
wi l l  need more data from this. 
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Aims: Pulmonary exacerbations (P Exs) are important feature of CF. They are 
expensive, and associated with poor quality of lit~. This study examines factors 
associated with P Exs in a large cohort in adolescent and adult patients. 
Patients: This is a cross sectional study on data collected in the South and West 
Regions ha England in 2CO2. Patients over 12 years were include. Data on age, 
gender, BMI, genetic profile, Swat test results, FEV1, infection with Pseudomonas 
aeruginosa (Pa) and on CF related diabetes were included. Exacerbation was 
regarded to be present when IV antibiotics were provided. Patients were divided 
into 4 groups: 1 (223 patients), no exacerbations; group 2 (158 patients); 1 2 annual 
exacerbations; group 3 (77 patients), 3-4 annual exacerbations; and group 4 (49 
patients) more than 4 exacerbations ha a year. 
Results: The need for IV antibiotics increased with decline in FEVI, the presence of 
Pa ha the sputum, CF related iabetes and with body mass index below 20. Rate of 
pulmonary exacerbations did not differ according to patients' age or gender. There 
was no difference ha either the concentration of sweat sodium or chloride 
concentration or genetic profile across categories of exacerbations. 
Conclusions: Reduced FEVI, infections with Pa, reduced BMI  and CF related 
diabetes are associated with increased pulmonary exacerbations a identified by the 
need of greater number of annual courses of IV antibiotics. 
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Up to 25 % of patients attending the Prague CF Centre are infected with B. 
cenc*zepacia (BC; formerly genomovar III) of the Burldmlderia cepacia complex. 
Despite this genomovar and strain homogeneity, the infection is manifested in its 
whole spectrum from its slow progression to the fulminant cepacia syndrome. 
Therefore, we sought o define the clinical factors influencing the survival after B. 
cenc~epacia nfection. 
Within 1994 2CO4, in total 96 patients were infected with BC. Using standard 
statistical tests (Cox model, Gehan Wilcoxon, Cox Mantel  and Ln  ranks tests), we  
analysed the fol lowing factors in terms of their possible role in patients urvival: 
lung function at the t ime of BC infection, change of FEV 1 per year during the first 
three years, Pseudomonas aeruginosa infection, nutritional status, pancreatic status, 
sweat chloride concentration, CFTR genotype and gender. 
We found statistically significant affect of the lung function (FEVI) at BC infection 
(p<0.CO1, b 0.057, i.e. eb~).947), of dynamic changes in FEV 1 (p<0.CO1, 
e b 0.741), and of chloride concentration (p 0.03, e b 1.025) on the survival. 
Inf luence of nutritional status, previous R aeruginosa infection and gender was not 
proven. The role of CFFR genotype and pancreatic status were not reliably 
evaluated due to a small number of non-censored observations in the group with 
mild mutations and pancreatic sufficiency (p value was close to 0.05). 
Results are in an agreement with published data about bad lung functions and their 
further decline worsening the infection prognosis. Our data indicate that patients 
with milder impairment of CFFR function may have less severe course of the BC 
infection. 
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